. The study found that treatment with certain disease-modifying antirheumatic drugs, specifically methotrexate and TNF inhibitors, was associated with a reduced risk of developing interstitial lung disease in patients with rheumatoid arthritis. This highlights the potential benefits of these medications beyond managing joint symptoms. Sparks emphasizes the importance of further research to confirm these findings and determine the best treatment approaches for patients with both rheumatoid arthritis and interstitial lung disease.
Source link
VIDEO: ‘Provocative’ observational study assesses DMARD use in RA-ILD
